Search Results - "Tuma, S"

ALK Gene Amplified in Most Inflammatory Breast Cancers by Tuma, Rabiya S.

“…Inflammatory breast cancer (IBC) is a rare form of the disease that differs substantially from noninflammatory breast cancer in presentation and response to…”
Get full text

Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors by Tuma, Rabiya S

“…Trastuzumab (Herceptin) is approved for the treatment of breast cancer patients whose tumors express a high level of the drug's target HER2/neu. Yet at least…”
Get full text

Immunotherapies in clinical trials: do they demand different evaluation tools? by Tuma, Rabiya S

“…Melanoma patients and immunotherapy researchers alike had cause to celebrate in late March when the US Food and Drug Administration approved ipilimumab…”
Get full text

Origin of Ovarian Cancer May Have Implications for Screening by Tuma, Rabiya S.

“…Ovarian cancer, like most malignancies, is named for the organ from which it arises. At least that was what clinicians and scientists thought. More recently,…”
Get full text

Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug by Tuma, Rabiya S

“…Two research groups report that melanoma tumors use multiple distinct routes to get around PLX4032. The drug works by inhibiting the mutated B-RAF, which…”
Get full text

Enthusiasm for Antibody-Drug Conjugates by Tuma, Rabiya S.

“…On Aug 19, the U.S. Food and Drug Administration approved brentuximab vedotin (Adcetris) for the treatment of Hodgkin lymphoma and a rare lymphoma known as…”
Get full text

New Tests for Prostate Cancer May Be Nearing the Clinic by Tuma, Rabiya S

“…The prostate-specific antigen (PSA) test to detect prostate cancer is notoriously weak on specificity. It not only has a substantial rate of false-positive…”
Get full text

Prepping omics for the clinic by Tuma, Rabiya S

“…The much-anticipated Institute of Medicine (IOM) report Evolution of Translational 'Omics: Lessons Learned and the Path Forward, released on Mar 23, 2012,…”
Get full text

Large-scale genome projects enter the clinic on both sides of the Atlantic by Tuma, Rabiya S

“…Genetic testing has become more common in cancer care in recent years. However, nearly all such tests are limited to a few genetic alterations that affect…”
Get full text

Functional Screens Take On the Cancer Genome by Tuma, Rabiya S.

“…Data are pouring out of cancer genome projects at an ever-increasing clip. Yet the list of genetic alterations that these projects generate yields only part of…”
Get full text

Targeted Epigenetic Therapies: The Next Frontier? by Tuma, Rabiya S

“…On Sep 8, investigators published two independent reports online--one in Science and one in the New England Journal of Medicine--showing that mutations in an…”
Get full text

Epigenetic Therapies Move Into New Territory, but How Exactly Do They Work? by Tuma, Rabiya S.

“…Although several drugs aimed at reversing epigenetic modifications--nonsequence changes in DNA--are already the standard of care for some malignancies, the…”
Get full text

Efficacy of Safety-Engineered Device Implementation in the Prevention of Percutaneous Injuries: A Review of Published Studies by Tuma, SeJean, Sepkowitz, Kent A.

“…Nearly 6 years have passed since the Needlestick Safety and Prevention Act of 2000 was signed into law. We reviewed studies published since 1995 that evaluated…”
Get full text

Measuring the importance of PSA velocity by Tuma, Rabiya S

“…The prostate-specific antigen (PSA) test is still widely used to determine whether a man should undergo a biopsy for prostate cancer. In recent years, PSA…”
Get full text

Strides in Melanoma Announced: Maximizing Value Comes Next by Tuma, Rabiya S.

“…After 30 years of negative phase III trials, melanoma research turned a corner last year when a large randomized phase III trial showed that ipilimumab…”
Get full text

New Law May Be Having Some Effect on Publication Bias by Tuma, Rabiya S.

“…Positive trials get reported more often than negative trials, according to many studies. And despite efforts in the past decade to combat publication bias, it…”
Get full text

Calls for New Reporting Standards, Quality Control in Microarrays by Tuma, Rabiya S

“…Concerns about the quality of microarray data in three Duke University cancer trials have simmered for several years. Then in July, after evidence surfaced…”
Get full text

Inconsistency of HER2 Test Raises Questions by Tuma, Rabiya S.

“…The tests that determine who gets the powerful breast cancer drug trastuzumab (Herceptin) may not be as reliable as previously thought, researchers report…”
Get full text

Large Trials, Small Gains: Is Change on the Way? by Tuma, Rabiya S

“…Large phase III trials designed to detect small differences in progression-free or overall survival have become common in oncology. Yet a growing number…”
Get full text

Stimulus Funds Force Hard Look at Comparative Effectiveness Research by Tuma, Rabiya S.

“…Two much-anticipated national reports on comparative effectiveness research appeared at the end of June, a first step toward spending the economic stimulus…”
Get full text